ASND ascendispharma.com Net earnings per share for the last 12 months

Public company logo of Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S (ASND) faces a fierce race for speed-to-market for drugs within the rare disease niche. The company is currently transitioning toward product commercialization, which ensures financial autonomy. Success is based on the TransCon method and the academic culture of Danish chemists. The rolling earnings per share trend visualizes these processes, while the 13.08 indicator reflects the current dynamics of per-unit income.

ASND (Ascendis) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/12/2026

Analytical breakdowns and data insights for company Ascendis Pharma AS (ASND)

- stock price and consensus target price:
Stock Price Ascendis Pharma A/S|ASND - Average Forecast Price
- market capitalization data:
Market Valuation Ascendis Pharma A/S|ASND - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share Ascendis Pharma|ASND - Book Capitalization|Market Capitalization to Book Value Ratio ascendispharma.com|ASND - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Ascendis Pharma A/S|ASND - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ascendis Pharma Inc.|ASND - Company Debts|Debts to Book Capitalization Ascendis Pharma A/S|ASND - Long-Term Debt Volume|Company Short-Term Debt Ascendis Pharma|Quick Liquidity ascendispharma.com
- net income and valuation multiples indicators:
ASND - Net Income|Projected Future Earnings Ascendis Pharma A/S|ASND - P/E Multiple|Future Price to Earnings Ascendis Pharma|ASND - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Ascendis Pharma A/S|ASND - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Ascendis Pharma|ASND - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months ascendispharma.com|ASND - Earnings per share growth this year|Earnings growth forecast for next year Ascendis Pharma A/S
Fundamental company valuation:Ascendis Pharma A/S (ASND)
Mass-produced product of Ascendis Pharma Inc.

Ascendis Pharma A/S (ASND) is strengthening its position in the pharmaceutical market by replacing daily therapies with long-acting injections powered by the TransCon platform. The effectiveness of this strategy is quantified through the ratio of net income to the number of shares over a rolling year, which filters out issuance noise and allows for an assessment of real per-share returns based on the net income per share dynamics over the last 12 months.

Competitors of Ascendis Pharma A/S

Madrigal Pharmaceuticals - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months corcept.com|RYTM (Rhythm Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|AKRO: Earnings per share for the last four quarters|MTSR (Metsera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MoonLake Corp|Net earnings per share (EPS TTM) CRNX|Earnings per share for the last twelve months NAMS (newamsterdampharma.com)|Earnings per share for the last twelve months Soleno Therapeutics, Inc. SLNO|Amicus Therapeutics Inc (FOLD) - Net earnings per one share for the last twelve months|ETNB - Earnings per share for the last twelve months|AGIO: Earnings per share for the last twelve months|GPCR: Net earnings per share (EPS TTM)|MDXG - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Rezolute|Lexicon Pharmaceuticals Inc (LXRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MBX Bio (MBX)|Net earnings per share for the last 12 months Altimmune Pharma ALT|Net earnings per share (EPS TTM) AARD (Aardvark Therapeutics Inc)|Net earnings per share (EPS TTM) sagimet.com SGMT|BIOA - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Biomea Fusion Inc BMEA|QNCX: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Fractyl Health, Inc|VTVT (vTv Therapeutics, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Agape ATP Corp. ATPC|Earnings per share for the last twelve months Pluri Inc. (PLUR)|synlogictx.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) LPCN (Lipocine Corp)|MTNB: Earnings per share for the last 12 months|Spruce Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters galecto.com GLTO|Carmell (CTCX) - Earnings per share for the last twelve months|LUMO - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months ONVO|RDUS: Earnings per share for the trailing year